Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$14.83 +3.3%	$12.32	$5.31 ▼ $17.43	$1.07B	1.71	3.65 million shs	2.67 million shs
CRON Cronos Group	$2.60	$2.19	$1.60 ▼ $2.77	$995.90M	1.01	3.92 million shs	5.83 million shs
PRAX Praxis Precision Medicines	$45.54 -1.0%	$49.18	$26.70 ▼ $91.83	$967.90M	2.62	508,628 shs	275,873 shs
SCPH scPharmaceuticals	$5.50 -0.2%	$4.75	$1.94 ▼ $6.28	$293.67M	0.4	1.86 million shs	4.38 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+1.49%	+5.83%	+23.28%	+18.89%	+138.37%
CRON Cronos Group	+1.56%	+1.56%	+29.35%	+31.31%	+20.93%
PRAX Praxis Precision Medicines	-1.98%	-0.84%	-17.82%	+19.21%	-9.93%
SCPH scPharmaceuticals	-0.18%	+20.57%	+1.10%	+55.65%	+11.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.7191 of 5 stars	3.4	1.0	0.0	4.0	0.0	1.9
CRON Cronos Group	1.7717 of 5 stars	0.0	3.0	0.0	3.1	0.0	2.5
PRAX Praxis Precision Medicines	1.689 of 5 stars	3.4	1.0	0.0	2.8	1.7	0.0
SCPH scPharmaceuticals	4.1303 of 5 stars	3.0	5.0	4.2	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.86	Moderate Buy	$17.33	16.88% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	88.57% Upside
SCPH scPharmaceuticals	2.00	Hold	$12.00	118.18% Upside

Current Analyst Ratings Breakdown

Latest SCPH, PRAX, CRMD, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral
8/25/2025	SCPH scPharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
8/25/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	25.47	N/A	N/A	$2.96 per share	5.01
CRON Cronos Group	$117.61M	8.47	$0.00 per share	5,587.55	$2.95 per share	0.88
PRAX Praxis Precision Medicines	$8.55M	112.12	N/A	N/A	$19.21 per share	2.37
SCPH scPharmaceuticals	$36.33M	8.07	N/A	N/A	($0.40) per share	-13.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	19.77	15.78	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	52.00	86.67	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	11/12/2025 (Estimated)

Latest SCPH, PRAX, CRMD, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
CRON Cronos Group	N/A	24.65	23.53
PRAX Praxis Precision Medicines	N/A	6.31	6.31
SCPH scPharmaceuticals	3.86	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
CRON Cronos Group	8.71%
PRAX Praxis Precision Medicines	67.84%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
CRON Cronos Group	7.30%
PRAX Praxis Precision Medicines	2.70%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

SCPH, PRAX, CRMD, and CRON Headlines

Recent News About These Companies

Maxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)

August 27 at 3:29 PM | marketbeat.com

Maxim Group Downgrades scPharmaceuticals (NASDAQ:SCPH) to Hold

August 27 at 2:31 AM | americanbankingnews.com

scPharmaceuticals downgraded to Hold from Buy at Maxim

August 26 at 12:37 AM | msn.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

August 26 at 7:35 PM | tmcnet.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

August 26 at 5:58 PM | businesswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

August 26 at 10:32 AM | globenewswire.com

Stonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPH

August 26 at 7:38 AM | marketbeat.com

scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum

August 25, 2025 | msn.com

CT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M deal

August 25, 2025 | hartfordbusiness.comH

MannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M deal

August 25, 2025 | fiercepharma.comF

SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind

August 25, 2025 | globenewswire.com

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

August 25, 2025 | businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

August 25, 2025 | businesswire.com

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

August 25, 2025 | globenewswire.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in July

August 21, 2025 | marketbeat.com

scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111

August 14, 2025 | msn.com

scPharmaceuticals Q2 2025 Earnings Call Highlights Growth

August 14, 2025 | theglobeandmail.com

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

August 14, 2025 | globenewswire.com

scPharmaceuticals management to meet with Craig-Hallum

August 12, 2025 | msn.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Acquired by King Luther Capital Management Corp

August 12, 2025 | marketbeat.com

Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to "Hold"

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, PRAX, CRMD, and CRON Company Descriptions

CorMedix NASDAQ:CRMD

$14.83 +0.48 (+3.34%)

Closing price 04:00 PM Eastern

Extended Trading

$14.88 +0.04 (+0.30%)

As of 07:55 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Cronos Group NASDAQ:CRON

$2.60 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 -0.02 (-0.58%)

As of 07:57 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Praxis Precision Medicines NASDAQ:PRAX

$45.54 -0.45 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$45.52 -0.02 (-0.05%)

As of 05:38 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

scPharmaceuticals NASDAQ:SCPH

$5.50 -0.01 (-0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$5.51 +0.01 (+0.16%)

As of 04:37 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time